Hoping to challenge Gilead Sciences, the leader in H.I.V. drugs, the pharmaceutical giants GlaxoSmithKline and Pfizer said Thursday that they would form a specialty company to research, develop and market treatments for H.I.V., the virus that causes AIDS.